Symdeko Seen to Favor Weight Gain, Limit Hospital Stays in Real-life Study

Symdeko Seen to Favor Weight Gain, Limit Hospital Stays in Real-life Study

297930

Symdeko Seen to Favor Weight Gain, Limit Hospital Stays in Real-life Study

Symdeko (tezacaftor/ivacaftor) favors weight gain, shortens hospital stays, and reduces the number of days on antibiotics in patients with cystic fibrosis (CF), a real-world study of its use at a Scottish clinic reported. However, no significant benefits in patients’ lung function were seen over about a year of follow-up. The study, “Tezacaftor-ivacaftor use in routine care of adults with cystic fibrosis: a medicine use evaluation,” was published in the European Journal of Hospital Pharmacy. Marketed…

You must be logged in to read/download the full post.